Start cervical cancer screening on Saba February 7th 2022, a pilot for population screening for cervical cancer will start on Saba. All women between 30 and 60 years, will be invited to participate in the coming three years.
New WHO Collaborating Centre hosted by RIVM combines laboratory preparedness and biorisk RIVM has been designated WHO Collaborating Centre for Laboratory Preparedness and Response for High Threat Pathogens and Biorisk by the World Health Organization (WHO).
The 13-week scan now available for pregnant women Since 1 September, pregnant women in the Netherlands can have an early ultrasound scan to detect physical abnormalities in their unborn child: the 13-week scan.
Breast cancer screening resumes on Bonaire after COVID-19 hiatus Women aged 50 to 75 years on Bonaire can participate in the breast cancer screening programme again as of Wednesday, May 26, 2021. This was temporarily halted in 2020 due to the COVID-19 pandemic.
More reports of adverse effects of implants in 2019 In 2019, the Dutch reporting centre for adverse effects of medical implants (MEBI) received 397 reports of suspected adverse effects. The reports concerned 462 implants.
Mesh implants intended to treat pelvic organ prolapse Synthetic mesh are used to treat patients with pelvic organ prolapse.
Environmental radioactivity in the Netherlands : Results in 2017 RIVM reports annually on the level of radioactivity that occurs under normal circumstances in the environment and food.
A guide for the safe reuse of diaper and incontinence materials RIVM has developed a step-by-step plan for the safe reuse of diapers and incontinence material. This plan provides recyclers and licensing authorities with tools to carry out a risk assessment.
Summary International Expert Meeting on breast implant-associated lymphoma On November 19th 2018, RIVM organised an international expert meeting on a rare type of lymphoma that is associated with breast implants.
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).